Peer-reviewed veterinary case report
A gliclazide complex based on palladium towards Alzheimer's disease: promising protective activity against Aβ-induced toxicity in.
- Journal:
- Chemical communications (Cambridge, England)
- Year:
- 2022
- Authors:
- García-García, Amalia et al.
- Affiliation:
- Department of Inorganic Chemistry · Spain
Abstract
A new palladium coordination compound based on gliclazide with the chemical formula [Pd(glz)] (where glz = gliclazide) has been synthesized and characterised. The structural characterization reveals that this material consists of mononuclear units formed by a Pdion coordinated to two molecules of the glz ligand, in which palladium ions exhibit a distorted plane-square coordination sphere. This novel material behaves like a good and selective inhibitor of butyrylcholinesterase, one of the most relevant therapeutic targets against Alzheimer's disease. Analysis of the enzyme kinetics showed a mixed mode of inhibition, the title compound being capable of interacting with both the free enzyme and the enzyme-substrate complex. Finally, the palladium compound shows promising protective activity against Aβ-induced toxicity in themodel, which has never been reported.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication: https://pubmed.ncbi.nlm.nih.gov/34994366/